Answers are grounded in this paper and cite their sources.
AZD9291 was highly active in patients with lung cancer with the EGFR T790M mutation who had had disease progression during prior therapy with EGFR tyrosine kinase inhibitors. (Funded by AstraZeneca; ClinicalTrials.gov number, NCT01802632.).
No takes yet. Share an insight, caveat, or question.
Jänne et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: